News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Bone Marrow Cancer Drug Wows In Late-Stage Study


12/6/2013 7:07:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said on Friday. A Phase III trial found the drug, dubbed LBH589 when combined with bortezomib and dexamethasone, significantly extended progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma compared to bortezomib and dexamethasone alone. Multiple myeloma is a cancer that starts in plasma cells in bone marrow and disrupts the production of normal blood cells.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES